Catalyst Pharmaceuticals Inc. (CN2)
XBER 
Summary
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Ahead of Catalyst (CPRX) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Catalyst (CPRX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Catalyst Pharmaceuticals: Clear Path Forward For Growth In 2 FDA-Approved Drugs
Catalyst Pharmaceuticals management asserts a $1B+ LEMS market opportunity, estimating 3,600–5,400 addressable patients, with growth driven by improved diagnosis and market penetration. Recent presentations highlight 15–20% continuous growth in LEMS, with strategic emphasis on both idiopathic and cancer-associated segments to expand FIRDAPSE's reach. In addition to LEMS, Catalyst controls North American rights to the DMD drug AGAMREE, which is enjoying significant growth.
Catalyst Pharmaceuticals Inc. (CN2) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Catalyst Pharmaceuticals Inc. ever had a stock split?
Catalyst Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Richard John Daly CEO | XBER Exchange | US14888U1016 ISIN |
| US Country | 181 Employees | - Last Dividend | - Last Split | 8 Nov 2006 IPO Date |
Overview
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for individuals suffering from rare debilitating, chronic neuromuscular, and neurological diseases primarily in the United States. Founded in 2002 and headquartered in Coral Gables, Florida, Catalyst Pharmaceuticals takes a focused approach to tackle the challenges faced by people living with rare conditions. Through its commitment to these underserved patient communities, Catalyst aims to bring significant improvements to their quality of life by providing novel treatment options.
Products and Services
Firdapse (amifampridine phosphate tablets)
An approved medication for the treatment of adults with Lambert-Eaton Myasthenic Syndrome (LEMS), Firdapse works by improving the communication between nerves and muscles, offering symptomatic relief and improved muscle function. Catalyst Pharmaceuticals has taken steps to ensure Firdapse is available to those who need it, addressing a critical need within the LEMS community.
Ruzurgi (for pediatric LEMS patients)
Expanding on its commitment to providing solutions for LEMS, Catalyst developed Ruzurgi specifically for pediatric patients suffering from this condition. Ruzurgi represents a key development in pediatric care for LEMS, giving younger patients access to a treatment that is tailored to meet their unique needs.
Future Developments
Beyond its current offerings, Catalyst Pharmaceuticals is actively working on expanding the application of Firdapse for the treatment of other conditions, including MuSK antibody-positive myasthenia gravis and spinal muscular atrophy type 3. These initiatives signify the company’s ongoing commitment to exploring new therapeutic avenues and broadening the impact of its research and development activities.
Collaboration and License Agreements
Acknowledging the importance of strategic partnerships in the pharmaceutical industry, Catalyst Pharmaceuticals has entered into license agreements with BioMarin Pharmaceutical Inc. and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. These collaborations are pivotal in enhancing Catalyst's product portfolio and ensuring that patients have access to a broader range of treatment options.
